Dogwood reports Q1 EPS ($8.45) vs. ($1.68) last year

“There are no FDA approved treatments to manage the neuropathic pain often resulting from chemotherapy treatment,” said Greg Duncan, Chief Executive Officer of Dogwood (DWTX) Therapeutics. “We believe Halneuron’s clinically significant effects in treating both general cancer pain and chemotherapy induced neuropathic pain highlights the great potential to expand our NaV 1.7 research pipeline to other forms of pain, including diabetic peripheral neuropathy, post herpetic neuralgia and potentially acute surgical pain as well.”